Miglitol attenuates non-alcoholic steatohepatitis in diabetic patients.
Michiharu KomatsuNaoki TanakaTakefumi KimuraNaoyuki FujimoriKenji SanoAkira HoriuchiAyumi SugiuraTomoo YamazakiSoichiro ShibataSatoru JoshitaTakeji UmemuraAkihiro MatsumotoEiji TanakaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2018)
Miglitol appears to safely ameliorate NASH activity by attenuation of steatosis and lobular/portal inflammation. Appropriately powered controlled trials are warranted to validate our results.